ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
35.62
0.23%
US Tech 100
18,103.80
1.49%
S&P 500
5,300.60
1.03%
US Dollar vs CAD
1.36019
-0.38%
Bitcoin
65,574.14
6.54%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. NeuroSense Therapeutics Ltd (NRSN)

  7. NeuroSense Therapeutics Ltd (NRSN) News

NRSN

NeuroSense Therapeutics (NRSN)

NeuroSense Therapeutics Ltd
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:NRSN
DateTimeSourceHeadlineSymbolCompany
05/14/20248:05AMPR Newswire (US)NeuroSense Partners with PhaseV to Optimize Upcoming ALS Phase 3 Trial Using Advanced Causal Machine LearningNASDAQ:NRSNNeuroSense Therapeutics Ltd
05/07/20247:45AMPR Newswire (US)NeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating Statistically Significant Slowing of Disease Progression in High-Risk ALS PatientsNASDAQ:NRSNNeuroSense Therapeutics Ltd
05/02/20248:19AMPR Newswire (US)NeuroSense Announces First Quarter 2024 Business UpdateNASDAQ:NRSNNeuroSense Therapeutics Ltd
04/22/20247:30AMPR Newswire (US)NeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's DiseaseNASDAQ:NRSNNeuroSense Therapeutics Ltd
04/18/20247:30AMPR Newswire (US)NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual MeetingNASDAQ:NRSNNeuroSense Therapeutics Ltd
04/12/20247:30AMPR Newswire (US)NeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024NASDAQ:NRSNNeuroSense Therapeutics Ltd
04/10/20246:16PMPR Newswire (US)NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private PlacementNASDAQ:NRSNNeuroSense Therapeutics Ltd
04/09/20247:30AMPR Newswire (US)NeuroSense Collaborates with Lonza to Identify Exosome-based Biomarkers, in order to Advance Neurodegenerative Disease Treatments and DiagnosticsNASDAQ:NRSNNeuroSense Therapeutics Ltd
04/05/20248:29AMPR Newswire (US)NeuroSense Announces Year End 2023 Financial Results and Provides Business UpdateNASDAQ:NRSNNeuroSense Therapeutics Ltd
02/22/20247:25AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NRSNNeuroSense Therapeutics Ltd
02/22/20247:25AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NRSNNeuroSense Therapeutics Ltd
02/21/20247:30AMPR Newswire (US)NeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM TrialNASDAQ:NRSNNeuroSense Therapeutics Ltd
02/13/202412:20PMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:NRSNNeuroSense Therapeutics Ltd
02/13/20249:14AMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:NRSNNeuroSense Therapeutics Ltd
02/07/20248:38AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NRSNNeuroSense Therapeutics Ltd
02/07/20248:27AMPR Newswire (US)NeuroSense Regains Compliance with NASDAQ Minimum Bid Price RuleNASDAQ:NRSNNeuroSense Therapeutics Ltd
01/09/20247:49AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NRSNNeuroSense Therapeutics Ltd
01/09/20247:48AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NRSNNeuroSense Therapeutics Ltd
01/09/20247:45AMPR Newswire (US)NeuroSense Recaps Positive 2023 Achievements Including Statistically Significant Slowing of Disease Progression in Phase 2b ALS Trial of PrimeC and Highlights Anticipated 2024 CatalystsNASDAQ:NRSNNeuroSense Therapeutics Ltd
12/27/20234:03PMEdgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:NRSNNeuroSense Therapeutics Ltd
12/27/20234:01PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NRSNNeuroSense Therapeutics Ltd
12/27/20234:00PMPR Newswire (US)NeuroSense Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity RequirementNASDAQ:NRSNNeuroSense Therapeutics Ltd
12/21/20237:45AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NRSNNeuroSense Therapeutics Ltd
12/14/20233:30PMEdgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:NRSNNeuroSense Therapeutics Ltd
12/14/20238:41AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NRSNNeuroSense Therapeutics Ltd
12/14/20238:24AMPR Newswire (US)NeuroSense Reports New Data: Statistically Significant Clinical Efficacy in Phase 2b ALS TrialNASDAQ:NRSNNeuroSense Therapeutics Ltd
12/05/20232:15PMEdgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:NRSNNeuroSense Therapeutics Ltd
12/05/20232:00PMEdgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:NRSNNeuroSense Therapeutics Ltd
12/05/20237:01AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NRSNNeuroSense Therapeutics Ltd
12/05/20237:00AMPR Newswire (US)NeuroSense's Phase 2b ALS Trial Achieves Primary Safety and Tolerability & Secondary Clinical Efficacy EndpointsNASDAQ:NRSNNeuroSense Therapeutics Ltd
 Showing the most relevant articles for your search:NASDAQ:NRSN

Your Recent History

NASDAQ
FFIE
Faraday Future Intellige...
USOTC
FBEC
FBEC Worldwide (CE)
USOTC
IQST
iQSTEL (QX)
USOTC
VXIT
Virexit Technologies (PK)
USOTC
EPAZ
Epazz (PK)
USOTC
RXMD
Progressive Care (QB)
AMEX
SPY
SPDR S&P 500
USOTC
SAPX
Seven Arts Entertainment (PK)
NYSE
GME
GameStop
USOTC
GDVM
Global Developments (PK)
USOTC
TDRK
TideRock Companies (PK)
USOTC
INKW
Greene Concepts (PK)
USOTC
AFFU
Affluence (PK)
NYSE
AMC
AMC Entertainment
USOTC
HNRC
Houston Natural Resources (PK)
USOTC
UATG
Umbra Applied Technologies (PK)
Delayed Upgrade Clock
ADVFN Logo

Canada
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved